Publication

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial

ANNÉE

2023

AUTEURS

Salfati D, Huot M, Aparicio T, Lepage C, Taieb J, Bouché O, Boige V, Phelip JM, Dahan L, Bennouna J, Le Malicot K, Boussari O, Gornet JM

CONGRÈS/REVUE

Dig Liver Dis

Etude

PRODIGE 9-FFCD-0802

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2022.12.018

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

ANNÉE

2023

AUTEURS

Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C

CONGRÈS/REVUE

Lancet Oncol

Etude

PRODIGE 47-FFCD-SURGIGAST

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/s1470-2045(23)00001-3

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

ANNÉE

2022

AUTEURS

de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, Taïeb J, Boige V, Bouché O, Chatellier T, Faroux R, François E, Jacquot S, Genet D, Mulot C, Olschwang S, Seitz JF, Aparicio T, Dahan L

CONGRÈS/REVUE

Ther Adv Med Oncol

Etude

PRODIGE 9-FFCD-0802

Localisation

Cancer Colorectal Métastatique

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1177/17588359221141307

A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.

ANNÉE

2022

AUTEURS

Hilmi M, Mitry E, Turpin A, Bouché 0, Metges JP, Ghiringhelli F, Trouilloud I, Roth G, Baumgaertner I, Borg C, Ammarguellat H, Guillet M, Rinaldi Y, Lecomte T, Louvet C, Lambert A, Hautefeuille V, Garcia-Larnicol ML, Henriques J , Neuzillet C

CONGRÈS/REVUE

ASCO

Etude

PRODIGE 63-GERCOR-TEDOPAM

Localisation

Cancer du Pancréas

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4148

A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.

ANNÉE

2022

AUTEURS

Hilmi M, Mitry E, Turpin A, Bouché 0, Metges JP, Ghiringhelli F, Trouilloud I, Roth G, Baumgaertner I, Borg C, Ammarguellat H, Guillet M, Rinaldi Y, Lecomte T, Louvet C, Lambert A, Hautefeuille V, Garcia-Larnicol ML, Henriques J , Neuzillet C

CONGRÈS/REVUE

ASCO

Etude

PRODIGE 63-GERCOR-TEDOPAM

Localisation

Cancer du Pancréas

LIEN PUBLICATIONS ASSOCIÉES

https://meetings.asco.org/abstracts-presentations/210687/poster

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma. A SCARCE-PRODIGE 60 randomized phase II study

ANNÉE

2022

AUTEURS

Kim S, Ghiringhelli F, De La Fouchardiere C,Francois E, Smith MD, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desrame J, Baba-Hamed N, Buecher B, Tougeron D, Bouché O, Chibaudel B, El Hajbi F, Garcia-Larnicol ML, Meurisse A, Vernerey D, Pernot S, Borg C

CONGRÈS/REVUE

ASCO

Etude

PRODIGE 60-GERCOR-SCARCE

Localisation

Cancer du Rectum et du Canal

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3508

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

ANNÉE

2022

AUTEURS

Tougeron D, Dahan L, El Hajbi F, KLe Malico K, Evesque L, Aparicio T, Bouche O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, bodere A, Phelip JM, Mabro M, Artru P, Louvet C

CONGRÈS/REVUE

ESMO

Etude

PRODIGE 59-FFCD-1707 DURIGAST

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://oncologypro.esmo.org/meeting-resources/esmo-congress/prodige-59-durigast-trial-a-randomised-phase-ii-study-evaluating-folfiri-plus-durvalumab-and-folfiri-plus-durvalumab-plus-tremelimumab-in-second

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

ANNÉE

2022

AUTEURS

Tougeron D, Dahan L, El Hajbi F, KLe Malico K, Evesque L, Aparicio T, Bouche O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, bodere A, Phelip JM, Mabro M, Artru P, Louvet C

CONGRÈS/REVUE

ASCO

Etude

PRODIGE 59-FFCD-1707 DURIGAST

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://ffcd.fr/images/Publications/2022/ASCO%202022%20DURIGAST%20v2.pdf

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

ANNÉE

2022

AUTEURS

Evrard C, Aparicio T, Soularue E, Le Malicot K, Desramé J, Botsen D, El Hajbi F, Gonzalez D, Lepage C, Bouché O, Tougeron D, On Behalf Of The Durigast-Prodige Investigators/Collaborators

CONGRÈS/REVUE

Biomedicines

Etude

PRODIGE 59-FFCD-1707 DURIGAST

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.3390/biomedicines10051211

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

ANNÉE

2022

AUTEURS

Boisteau E, François E, Aparicio T, Le Malicot K, Boulahssass R, Lecomte T, Laurent-Puig P, Guiu B, Paillaud E, Galais MP, Lopez-Trabada Ataz D, Tougeron D, Dourthe LM, Guimbaud R, Samalin E, Moreau M, Louvet C, Lepage C, Lièvre A

CONGRÈS/REVUE

Dig Liver Dis

Etude

PRODIGE 55-FFCD-1602 SOCRATE

Localisation

Cancer de l’Œsophage et de l’Estomac

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2022.03.001